Clinical Trial Update: Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and tolerability of 28 days of once-daily glycopyrronium bromide (NVA237) at 100 or 200 µg in moderate to severe chronic obstruc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• NVA237 (glycopyrronium bromide) (glycopyrronium bromide)

Snippet

Sponsor: Novartis | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Status: COMPLETED | Results posted: 2011-01-21